Viewing nowBukhwang Valsartan Tablets 160 mg
Valsartan 160mg
Tablet · Prescription medication
Bukhwang Pharmaceutical Co., Ltd.

MFDS item code 201103994 · Approved 2011.06.28 · Insurance code 642203080
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It is also indicated for the treatment of heart failure patients (NYHA Class II to IV) who cannot use ACE inhibitors. After myocardial infarction, it helps reduce the risk of mortality in patients with left ventricular dysfunction. In summary, this drug is effectively used for managing hypertension, specific heart failure, and preventing complications after myocardial infarction.
1. Essential hypertension Take with water during or between meals. It is recommended, if possible, to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with reduced intravascular fluid volume: For patients with reduced intravascular fluid volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis because there is no experience with use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Pediatric patients: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents younger than 18 years.
This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters; it should be discontinued immediately if pregnancy is confirmed. It is not safe to use this medication in patients with certain conditions, such as severe liver impairment, severe renal impairment, or hereditary angioedema. Additionally, extra caution is needed when administering this drug to elderly patients, patients with hyperkalemia, and patients with mild to moderate liver impairment, and dosage adjustments or frequent monitoring of their condition is required. When starting this medication, blood pressure may drop rapidly; thus, patients undergoing dialysis or those on diuretics, or those on strict sodium restriction should start with a low dose and be closely monitored. Due to the blood pressure-lowering effect, dizziness or lightheadedness may occur, and caution is advised when driving or operating machinery. This medication may increase potassium levels, so when taken with potassium-sparing diuretics or potassium supplements, serum potassium levels should be closely monitored. Furthermore, combining this medication with other antihypertensive drugs or non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the effectiveness of blood pressure control or affect kidney function, so consider consulting a doctor. Regular check-ups of liver and kidney functions are recommended during the course of this medication, and any unusual symptoms should be discussed with a healthcare provider immediately. Women who are pregnant or breastfeeding should avoid taking this medication; if it is necessary to take it, consultation with a healthcare professional is essential. In case of overdose, symptoms such as hypotension and altered consciousness may occur, and immediate medical attention should be sought. Lastly, this medication should be stored in a safe place out of reach of children, and transferring it to another container should be avoided as it can lead to deterioration of quality or accidents.
headache
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; it should be stored in a sealed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Light brown oval film-coated tablet
98 tablets (14 tablets/PTP x 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Bukhwang Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.